Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Neuropathic Pain Market – Insights

Neuropathic pain is a complex, chronic pain state that usually is accompanied by tissue injury. It may lead to damage, dysfunction, or injury of nerve fibers, thereby leading to misfiring of signals to other pain centers. The impact of a nerve fiber injury includes a change in nerve function both at the site of injury and areas around the injury.

The global neuropathic pain market is estimated to account for US$ 6,313.4 Mn in terms of value in 2019 and is expected to reach US$ 9,862.3 Mn by the end of 2027.

Global Neuropathic Pain Market: Drivers

High prevalence of cancer is expected to boost growth of the global neuropathic pain market over the forecast period. For instance, according to the World Health Organization, around 18.1 million new cases and 9.6 million deaths were registered due to cancer worldwide in 2018.

Moreover, increasing geriatric population is also expected to aid in growth of the market. For instance, according to the World Health Organization, geriatric population is expected to reach 2 billion by 2050, up from 900 million in 2015.

North America region held dominant position in the global neuropathic pain market in 2019, accounting for 35.9% share in terms of value, followed by Europe.

Neuropathic Pain  | Coherent Market Insights

Global Neuropathic Pain Market: Restraints 

Incomplete pain relief is expected to hinder growth of the global neuropathic pain market. For instance, use of strong opioids such as oxycodone in the treatment of neuropathic pain often leads to low reduction in pain.

Moreover, side-effects of medications are also expected to limit growth of the market. Use of opioids and steroids may lead to complications such as heart attack, kidney failure, and damage in lungs.

Global Neuropathic Pain Market: Opportunities

High prevalence of neuropathic-like pain in psoriatic arthritis is expected to offer lucrative growth opportunities for players in the market. For instance, in July 2019, researchers from Cardiff University, U.K., reported that neuropathic-like pain as evidence of abnormal pain processing is common in patients with psoriatic arthritis. 

Moreover, R&D in neuropathic pain is also expected to aid in growth of the market. For instance, in March 2020, researchers from Heidelberg University, Germany, reported assessment of the phytochemical composition and the possible prophylactic effects of an aqueous ethanol extract of Haematoxylon campechianum flowers on peripheral neuropathic pain in a chronic constriction injury rat model.

Neuropathic Pain  | Coherent Market Insights

Anticonvulsants segment in the global neuropathic pain market was valued at US$ 2,548.1 Mn in 2019 and is expected to reach US$ 4,310.3 Mn by 2027 at a CAGR of 6.4% during the forecast period.

Market Trends/Key Takeaways

Use of flavonoids can be effective in the treatment of neuropathic pain due to spared nerve injury, spinal nerve ligation, partial sciatic nerve injury, diabetes-induced neuropathy, chemotherapy-induced neuropathy, and chronic constriction injury.  

Several studies have demonstrated that electroacupuncture can be effective in decreasing neuropathic pain. For instance, in January 2020, researchers from Huazhong Agricultural University, China, demonstrated that Synaptotagmin 1 (Syt-1), a synaptic vesicle protein for regulating exocytosis of neurotransmitters, impairs neuropathic pain and that electroacupuncture relieves neuropathic pain through down-regulating spinal Syt-1.

Global Neuropathic Pain Market: Competitive Landscape  

Major players operating in the global neuropathic pain market include, Pfizer, Inc., Johnson & Johnson Services, Inc., Sanofi S.A., Eily Lily and Company, GlaxoSmithKline PLC, Biogen Idec., Bristol-Myers Squibb, Baxter Healthcare Corporation, and Depomed, Inc.

Global Neuropathic Pain Market: Key Developments

Major players in the market are focused on approval and launch of new products in order to expand their product portfolio. For instance, in March 2020, Senzer Pharmaceuticals secured the Investigational New Drug application and data package for its ongoing FDA registration program from its former US strategic partner in order to get approval for its cannabinoid respiratory device for the treatment of side effects induced by anti-cancer treatments, specifically nausea, vomiting, and neuropathic pain.

Major players in the market are also focused on conducting clinical trials to expand their product portfolio. For instance, in February 2020, NoNO Inc., a privately-held biotechnology company, reported that novel peptide, nerinetide, without prior administration of alteplase, demonstrated medically important improvements in patients with acute ischemic stroke, in a multicenter, randomized, study.

Neuropathic pain is a condition which involves pain caused due to damage or diseases affecting the nervous system. These conditions may include diseases such as diabetes causing diabetic neuropathy, chemotherapy induced neuropathic pain, and trigeminal neuralgia. Diabetic neuropathy is the damage caused to the nerve due to diabetes which often leads to pain and numbness in feet or lower legs. The pain can be experienced in other parts of the body such as hips, wrist and back depending upon the effect of neuropathy. There are different types of neuropathy such as focal neuropathy, proximal neuropathy, peripheral neuropathy and autonomic neuropathy. An estimated 50% of diabetic population suffers from diabetic neuropathy across the globe. Further, as per CDC estimates,   6-7 people per 1000 diabetic population suffer from diabetic neuropathy in the U.S.

Restraints of the Global Neuropathic Pain Market

Factors such as availability of less number of FDA approved medications, and incomplete pain relief, are expected to restrain growth of the global neuropathic pain market.

Key features of the study:

  • This report provides in-depth analysis of the global neuropathic pain market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2019–2027), considering 2018, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the global neuropathic pain market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Pfizer, Inc., Johnson & Johnson Services, Inc., Sanofi S.A., Eliy Lily and Company, GlaxoSmithKline PLC, Biogen Idec., Bristol-Myers Sqibb, Baxter Healthcare Corporation, and Depomed, Inc.
  • Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The global neuropathic pain market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

  • Global Neuropathic Pain Market, By Drug Class:
    • Tricyclic Anti-Depressant
    • Anticonvulsant
    • Local Anaesthesia
    • Opioids
    • Steroids
    • Others
  • Global Neuropathic Pain Market, By Indication:
    • Diabetic neuropathy
    • Chemotherapy-induced Peripheral neuropathy
    • Other
  • Global Neuropathic Pain Market, By Distribution Channel:
    • Retail Pharmacies
    • Drug Store
    • Online Pharmacies
  • Global Neuropathic Pain Market, By Geography:
    • North America
      • By Drug Class
        • Tricyclic Anti-Depressant
        • Anticonvulsant
        • Local Anaesthesia
        • Opioids
        • Steroids
        • Others
      • By Indication
        • Diabetic neuropathy
        • Chemotherapy-induced Peripheral neuropathy
        • Other
      • By Distribution Channel
        • Retail Pharmacies
        • Drug Store
        • Online Pharmacies
      • By Country:
        • U.S.
        • Canada
    • Europe
      • By Drug Class
        • Tricyclic Anti-Depressant
        • Anticonvulsant
        • Local Anaesthesia
        • Opioids
        • Steroids
        • Others
      • By Indication
        • Diabetic neuropathy
        • Chemotherapy-induced Peripheral neuropathy
        • Other
      • By Distribution Channel
        • Retail Pharmacies
        • Drug Store
        • Online Pharmacies
      • By Country:
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Drug Class
        • Tricyclic Anti-Depressant
        • Anticonvulsant
        • Local Anaesthesia
        • Opioids
        • Steroids
        • Others
      • By Indication
        • Diabetic neuropathy
        • Chemotherapy-induced Peripheral neuropathy
        • Other
      • By Distribution Channel
        • Retail Pharmacies
        • Drug Store
        • Online Pharmacies
      • By Country:
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • By Drug Class
        • Tricyclic Anti-Depressant
        • Anticonvulsant
        • Local Anaesthesia
        • Opioids
        • Steroids
        • Others
      • By Indication
        • Diabetic neuropathy
        • Chemotherapy-induced Peripheral neuropathy
        • Other
      • By Distribution Channel
        • Retail Pharmacies
        • Drug Store
        • Online Pharmacies
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East:
      • By Drug Class
        • Tricyclic Anti-Depressant
        • Anticonvulsant
        • Local Anaesthesia
        • Opioids
        • Steroids
        • Others
      • By Indication
        • Diabetic neuropathy
        • Chemotherapy-induced Peripheral neuropathy
        • Other
      • By Distribution Channel
        • Retail Pharmacies
        • Drug Store
        • Online Pharmacies
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Drug Class
        • Tricyclic Anti-Depressant
        • Anticonvulsant
        • Local Anaesthesia
        • Opioids
        • Steroids
        • Others
      • By Indication
        • Diabetic neuropathy
        • Chemotherapy-induced Peripheral neuropathy
        • Other
      • By Distribution Channel
        • Retail Pharmacies
        • Drug Store
        • Online Pharmacies
      • By Country/Region:
        • Central Africa
        • South Africa
        • North Africa
  • Company Profiles
    • Pfizer, Inc.*
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • Johnson & Johnson Services, Inc.
    • Sanofi S.A.
    • Eily Lily and Company
    • GlaxoSmithKline PLC
    • Biogen Idec.
    • Bristol-Myers Squibb
    • Baxter Healthcare Corporation
    • Depomed, Inc.

 “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Drug Class
      • Market Snippet, By Indication
      • Market Snippet, By Distribution Channel
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Regulatory Scenario
    • PEST Analysis
    • Pipeline Analysis
  4. Global Neuropathic Pain Market, By Drug Class, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Tricyclic Anti-Depressant
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Anticonvulsant
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Local Anaesthesia
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Opioids
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Steroids
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
    • Others
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
      • Segment Trends
  5. Global Neuropathic Pain Market, By Indication, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Diabetic neuropathy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Chemotherapy-induced Peripheral neuropathy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Other
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global Neuropathic Pain Market, By Distribution Channel, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • Retail Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Drug Store
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Online Pharmacies
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  7. Global Neuropathic Pain Market, By Regions, 2019 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017–2027
      • Segment Trends
    • North America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Europe
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • U.K.
        • Germany
        • Italy
        • France
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • ASEAN
        • Australia
        • South Korea
        • Rest of Asia Pacific
    • Latin America
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Middle East
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  8. Competitive Landscape
    • Company Profiles
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Johnson & Johnson Services, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Sanofi S.A.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Eily Lily and Company
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • GlaxoSmithKline PLC
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Biogen Idec.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Bristol-Myers Squibb
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Baxter Healthcare Corporation
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Depomed, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  9. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 31 market data tables and 24 figures on “Neuropathic Pain Market – Global forecast to 2027.

Frequently Asked Questions

The global neuropathic pain market is estimated to reach US$ 9,862.3 Million by the end of 2027.
Major players operating in the global neuropathic pain market include Pfizer, Inc., Johnson & Johnson Services, Inc., Sanofi S.A., Eily Lily and Company, GlaxoSmithKline PLC, Biogen Idec., Bristol-Myers Squibb, Baxter Healthcare Corporation, and Depomed, Inc.
Side-effects associated with medications is one of the major factors that is expected to hamper growth of the market over the forecast period.
High prevalence of cancer is one of the major factors that is expected to propel growth of the market over the forecast period.
The global neuropathic pain market is estimated to account for US$ 6,313.4 Mn in terms of value in 2019.
Among regions, North America is expected to hold dominant position in the global neuropathic pain market in 2019, accounting for 35.9% share, in terms of value, followed by Europe.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner